Ibrutinib Response in Cutaneous Transformed Lymphoplasmacytic Lymphoma

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35844727

Authors

Kaleigh E Lindholm

Peter A Forsberg

Mark D Ewalt

Affiliations

Soon will be listed here.

Citing Articles

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma.

Lindholm K, Forsberg P, Ewalt M EJHaem. 2022; 2(3):565-568.

PMID: 35844727 PMC: 9176001. DOI: 10.1002/jha2.253.

References

Davids M, Brown J . Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014; 10(6):957-67. PMC: 4632638. DOI: 10.2217/fon.14.51. View

Lindholm K, Forsberg P, Ewalt M . Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma. EJHaem. 2022; 2(3):565-568. PMC: 9176001. DOI: 10.1002/jha2.253. View

Treon S, Xu L, Yang G, Zhou Y, Liu X, Cao Y . MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367(9):826-33. DOI: 10.1056/NEJMoa1200710. View

Graf S, Cassaday R, Morris K, Voutsinas J, Wu Q, Behnia S . Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020; 21(3):176-181. PMC: 7904587. DOI: 10.1016/j.clml.2020.11.023. View

Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros L . Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol. 2003; 120(2):246-53. DOI: 10.1309/R01V-XG46-MFCD-VNHL. View

Durot E, Tomowiak C, Michallet A, Dupuis J, Hivert B, Lepretre S . Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017; 179(3):439-448. DOI: 10.1111/bjh.14881. View

Hunter Z, Xu L, Yang G, Zhou Y, Liu X, Cao Y . The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2013; 123(11):1637-46. DOI: 10.1182/blood-2013-09-525808. View

Hiemcke-Jiwa L, Leguit R, Radersma-van Loon J, Westerweel P, Rood J, Doorduijn J . Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. Leuk Lymphoma. 2017; 59(5):1256-1259. DOI: 10.1080/10428194.2017.1369074. View

Papanota A, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos M, Gavriatopoulou M . Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia. J Blood Med. 2019; 10:291-300. PMC: 6717707. DOI: 10.2147/JBM.S183997. View

10.

Herman S, Gordon A, Hertlein E, Ramanunni A, Zhang X, Jaglowski S . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23):6287-96. PMC: 3122947. DOI: 10.1182/blood-2011-01-328484. View

11.

Lee C, Rattu M, Kim S . A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract. 2014; 22(1):92-104. DOI: 10.1177/1078155214561281. View